References
- Weinstein R. Bone involvement in multiple myeloma. Am J Med 1992; 93: 591–592
- Rodriguez L H, Finkelstein J B, Schullenberger C C, Alexanian R. Bone healing in multiple myeloma with melphalan chemotherapy. Ann Int Med 1982; 76: 551–556
- Johnston C C, Slemenda C W, Melton L J. Clinical use of bone densitometry. N Engl J Med 1991; 324: 1105–1110
- Mariette X, Khalifa P, Ravaud P, Frija J, Laval-Jeantet M, Chastang C, et al. Bone densitometry in patients with multiple myeloma. Am J Med 1992; 93: 595–598
- Mariette X, Bergot C, Ravaud P, Roux C, Laval-Jeantet M, Broquet J C, et al. Evolution of bone densitometry in patients with multiple myeloma treated with conventional or intensive therapy. Cancer 1995; 76: 1559–1563
- Holmes J A, Evans W D, Coles R J, Ramashoye B, Whittaker J A. Dual energy X ray absorptiometry measurements of bone mineral density in myeloma. European J Hematology 1994; 53: 309–311
- Roux C, Ravaud P, Cohen-Solal M, De Vernejoul M C, Guillemant S, Cherrau B, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994; 15: 41–43
- Berenson J, Lichtenstein A, Porter L, Dimopoulos M, Bordoni R, George S, et al. Efficacy of patnidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–495
- Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I, for the Finnish Leukemia group. Randomised placebo controlled trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049–1052
- Belch A R, Bergsagel D E, Wilson K, O'Reilly S, Wilson J, Sutton D, et al. Effect of daily etidronate on osteolysis of multiple myeloma. J Clin One 1991; 9: 1397–1402
- Jagannath S, Vesole D H, Glenn L, Crowley J, Barlogie B. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell transplantation. Blood 1992; 80: 1666–1672
- Ellis R E. The distribution of active bone marrow in the adult. Phys Med Biol 1961; 5: 255–260
- Thornton T, Ballester O, Greenfield G. Progression of bone disease in multiple myeloma patients treated with high dose therapy and autologous stem cell transplantation. Blood 1996; 88: 481a
- Rosen L, Lichtenstein A, Heffernan M, Seaman J, Knight R, Berenson J. Serial β 2 microglobulin levels correlate with morbidity and mortality in multiple myeloma. Blood 1995; 86: 188a